Synthesis and Biological Activity of Hydroxamic Acid-Derived Vasopeptidase Inhibitor Analogues
摘要:
[GRAPHIC]Syntheses of novel hydroxamic acid-derived azepinones containing pendant mercaptoacyl groups or formyl hydroxamates are described. These new analogues of therapeutically important ACE and NEP inhibitors include unprecedented changes at the previously assumed essential acid component.
Synthesis and Biological Activity of Hydroxamic Acid-Derived Vasopeptidase Inhibitor Analogues
摘要:
[GRAPHIC]Syntheses of novel hydroxamic acid-derived azepinones containing pendant mercaptoacyl groups or formyl hydroxamates are described. These new analogues of therapeutically important ACE and NEP inhibitors include unprecedented changes at the previously assumed essential acid component.
PROCESS FOR PREPARING 2-ACETYLTHIO-3-PHENYL-PROPIONIC ACID AND THE SALTS THEREOF
申请人:ZAMBON GROUP S.p.A.
公开号:EP1056715B1
公开(公告)日:2002-06-12
US6080881A
申请人:——
公开号:US6080881A
公开(公告)日:2000-06-27
[EN] PROCESS FOR PREPARING 2-ACETYLTHIO-3-PHENYL-PROPIONIC ACID AND THE SALTS THEREOF<br/>[FR] PROCEDE DE PREPARATION D'ACIDE 2-ACETHYLTHIO-3-PHENYL-PROPIONIQUE ET DES SELS DE CET ACIDE
申请人:ZAMBON GROUP S.P.A.
公开号:WO1999042438A1
公开(公告)日:1999-08-26
(EN) It is described a process for preparing 2-acethylthio-3-phenyl-propionic acid and the salts thereof starting from 2-bromo-3-phenyl-propionic acid and potassium thioacetate in an organic solvent and in the presence of a phase transfer catalyst.(FR) Cette invention se rapporte à un procédé servant à préparer l'acide 2-acéthylthio-3-phényl-propionique et les sels de cet acide, en partant de l'acide 2-bromo-3-phényl-propionique et de thioacétate de potassium dans un solvant organique et en présence d'un catalyseur de transfert de phase.
Synthesis and Biological Activity of Hydroxamic Acid-Derived Vasopeptidase Inhibitor Analogues
作者:Andrew J. Walz、Marvin J. Miller
DOI:10.1021/ol025896m
日期:2002.6.1
[GRAPHIC]Syntheses of novel hydroxamic acid-derived azepinones containing pendant mercaptoacyl groups or formyl hydroxamates are described. These new analogues of therapeutically important ACE and NEP inhibitors include unprecedented changes at the previously assumed essential acid component.